These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31847605)

  • 1. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL).
    Ben-Barouch S; Kuruvilla J
    Expert Opin Investig Drugs; 2020 Jan; 29(1):15-21. PubMed ID: 31847605
    [No Abstract]   [Full Text] [Related]  

  • 2. A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma.
    Sylvain C
    Expert Rev Hematol; 2022 Mar; 15(3):195-201. PubMed ID: 35318887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
    Deng M; Zhang M; Xu-Monette ZY; Pham LV; Tzankov A; Visco C; Fang X; Bhagat G; Zhu F; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Choi WWL; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Hagemeister F; Alinari L; Li Y; Andreeff M; Xu B; Young KH
    J Hematol Oncol; 2020 Nov; 13(1):148. PubMed ID: 33148342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
    Casasnovas RO; Follows G; Zijlstra JM; Vermaat JSP; Kalakonda N; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi PF; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Ma X; Chamoun K; Shah J; Canales M; Maerevoet M; Shacham S; Kauffman MG; Goy A
    Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):24-33. PubMed ID: 34493477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
    Schuster M; Zijlstra J; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Follows G; Egyed M; Offner F; Vassilakopoulos T; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M; Maerevoet M
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):483-494. PubMed ID: 35078739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
    Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
    Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selinexor for the treatment of multiple myeloma.
    Podar K; Shah J; Chari A; Richardson PG; Jagannath S
    Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
    [No Abstract]   [Full Text] [Related]  

  • 9. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
    Benkova K; Mihalyova J; Hajek R; Jelinek T
    Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
    Kuruvilla J; Savona M; Baz R; Mau-Sorensen PM; Gabrail N; Garzon R; Stone R; Wang M; Savoie L; Martin P; Flinn I; Jacoby M; Unger TJ; Saint-Martin JR; Rashal T; Friedlander S; Carlson R; Kauffman M; Shacham S; Gutierrez M
    Blood; 2017 Jun; 129(24):3175-3183. PubMed ID: 28468797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
    Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
    Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
    Peterson TJ; Orozco J; Buege M
    Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
    Gounder MM; Zer A; Tap WD; Salah S; Dickson MA; Gupta AA; Keohan ML; Loong HH; D'Angelo SP; Baker S; Condy M; Nyquist-Schultz K; Tanner L; Erinjeri JP; Jasmine FH; Friedlander S; Carlson R; Unger TJ; Saint-Martin JR; Rashal T; Ellis J; Kauffman M; Shacham S; Schwartz GK; Abdul Razak AR
    J Clin Oncol; 2016 Sep; 34(26):3166-74. PubMed ID: 27458288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
    Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.
    Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
    Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Kasamon YL; Price LSL; Okusanya OO; Richardson NC; Li RJ; Ma L; Wu YT; Theoret M; Pazdur R; Gormley NJ
    Oncologist; 2021 Oct; 26(10):879-886. PubMed ID: 34132444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?
    Nishihori T; Baz R
    Expert Opin Drug Saf; 2020 Feb; 19(2):113-115. PubMed ID: 31910353
    [No Abstract]   [Full Text] [Related]  

  • 20. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
    Maerevoet M; Zijlstra JM; Follows G; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Van Den Neste E; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M
    J Hematol Oncol; 2021 Jul; 14(1):111. PubMed ID: 34271963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.